Endo Itsuro, Matsumoto Toshio
Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Medical Sciences.
Clin Calcium. 2010 May;20(5):700-8.
For the treatment of osteoporosis, anti-resorptive agents including bisphosphonates and raloxifene are widely used. As new anti-resorptive drugs, anti-RANKL antibody and cathepsin K inhibitor are under development. Among bone anabolic agents, daily subcutaneous injection of teriparatide will soon become available in Japan. In addition, new anabolic agents such as calcilitycs and anti-sclerostin antibody are under clinical or preclinical development for the treatment of osteoporosis.
对于骨质疏松症的治疗，包括双膦酸盐和雷洛昔芬在内的抗吸收药物被广泛使用。作为新型抗吸收药物，抗RANKL抗体和组织蛋白酶K抑制剂正在研发中。在骨形成促进剂中，每日皮下注射特立帕肽不久将在日本上市。此外，诸如卡尔西立和抗硬化蛋白抗体等新型骨形成促进剂正处于治疗骨质疏松症的临床或临床前研发阶段。
